HI
NVCR icon

Hudock Inc’s NovoCure NVCR Stock Holding History

Hudock Inc’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-500
Closed -$37K – 520
2022
Q3 		$37K Hold
500
– – 0.01% 351
2022
Q2 		$34K Hold
500
– – 0.01% 354
2022
Q1 		$41K Hold
500
– – 0.01% 345
2021
Q4 		$37K Hold
500
– – 0.01% 360
2021
Q3 		$58K Hold
500
– – 0.02% 301
2021
Q2 		$110K Hold
500
– – 0.03% 227
2021
Q1 		$66K Hold
500
– – 0.02% 280
2020
Q4 		$86K Hold
500
– – 0.03% 238
2020
Q3 		$55K Buy
500
+100
+25% +$8K 0.02% 266
2020
Q2 		$23K Hold
400
– – 0.01% 352
2020
Q1 		$26K Buy
+400
New +$31.6K 0.01% 296

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
NA
Nordwand Advisors Radnor, Pennsylvania $572M AUM 23.09% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Hudock Inc's NVCR Position: Q4 2022 in Review

Hudock Inc sold out of NovoCure (NVCR) in Q4 2022, closing a stake of 500 shares — an estimated $37K sold.

Hudock Inc first reported a position in NVCR in Q1 2020 and held it in 11 quarters. The position peaked at $110K in Q2 2021. 304 funds tracked by Wall St. Rank hold NVCR as of Q4 2022.

  • Hudock Inc reported no remaining NovoCure position as of Q4 2022 after selling out during the quarter.
  • Hudock Inc sold 500 NovoCure shares in Q4 2022, an estimated $37K.
  • Hudock Inc first reported a position in NovoCure in Q1 2020 and held it in 11 quarters.
  • Hudock Inc's NovoCure position peaked at $110K in Q2 2021.
  • 304 funds tracked by Wall St. Rank held NovoCure as of Q4 2022.

Based on Hudock Inc's 13F filing for Q4 2022, filed 8 Feb 2023.